Kiora Pharmaceuticals Total Assets Growth & History (KPRX)
Kiora Pharmaceuticals's total assets was $24.3M for fiscal 2025.
View full Kiora Pharmaceuticals company overviewKiora Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $24.3M | −$12.2M | −33.52% |
| 2024 | 2024-12-31 | $36.5M | $22.8M | +166.08% |
| 2023 | 2023-12-31 | $13.7M | −$5.0M | −26.59% |
| 2022 | 2022-12-31 | $18.7M | −$1.5M | −7.21% |
| 2021 | 2021-12-31 | $20.1M | $4.8M | +31.53% |
| 2020 | 2020-12-31 | $15.3M | $5.2M | +51.34% |
| 2019 | 2019-12-31 | $10.1M | −$4.2M | −29.19% |
| 2018 | 2018-12-31 | $14.3M | −$24,775 | −0.17% |
| 2017 | 2017-12-31 | $14.3M | $4.6M | +47.01% |
| 2016 | 2016-12-31 | $9.7M | $222,901 | +2.34% |
| 2015 | 2015-12-31 | $9.5M | $8.1M | +576.00% |
| 2014 | 2014-12-31 | $1.4M | — | — |
Kiora Pharmaceuticals quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $23.8M | −$8.2M | −25.57% |
| Q1 2026 | 2026-03-31 | $21.2M | −$12.8M | −37.60% |
| Q4 2025 | 2025-12-31 | $24.3M | −$12.2M | −33.52% |
| Q3 2025 | 2025-09-30 | $29.9M | −$8.6M | −22.45% |
| Q2 2025 | 2025-06-30 | $31.9M | −$8.9M | −21.73% |
| Q1 2025 | 2025-03-31 | $34.0M | −$8.4M | −19.84% |
| Q4 2024 | 2024-12-31 | $36.5M | $22.8M | +166.08% |
| Q3 2024 | 2024-09-30 | $38.5M | $22.6M | +142.25% |
| Q2 2024 | 2024-06-30 | $40.8M | $20.9M | +105.25% |
| Q1 2024 | 2024-03-31 | $42.4M | $25.9M | +156.78% |
| Q4 2023 | 2023-12-31 | $13.7M | −$5.0M | −26.59% |
| Q3 2023 | 2023-09-30 | $15.9M | −$1.8M | −10.00% |
| Q2 2023 | 2023-06-30 | $19.9M | $4.4M | +28.60% |
| Q1 2023 | 2023-03-31 | $16.5M | −$1.1M | −6.29% |
| Q4 2022 | 2022-12-31 | $18.7M | −$1.5M | −7.21% |
| Q3 2022 | 2022-09-30 | $17.7M | −$7.8M | −30.72% |
| Q2 2022 | 2022-06-30 | $15.5M | −$2.6M | −14.57% |
| Q1 2022 | 2022-03-31 | $17.6M | −$3.0M | −14.47% |
| Q4 2021 | 2021-12-31 | $20.1M | $4.8M | +31.53% |
| Q3 2021 | 2021-09-30 | $25.5M | $16.2M | +175.75% |
| Q2 2021 | 2021-06-30 | $18.1M | $7.1M | +65.04% |
| Q1 2021 | 2021-03-31 | $20.6M | $8.4M | +69.20% |
| Q4 2020 | 2020-12-31 | $15.3M | $5.2M | +51.34% |
| Q3 2020 | 2020-09-30 | $9.2M | $377,485 | +4.26% |
| Q2 2020 | 2020-06-30 | $11.0M | $71,360 | +0.65% |
| Q1 2020 | 2020-03-31 | $12.2M | −$252,182 | −2.03% |
| Q4 2019 | 2019-12-31 | $10.1M | −$4.2M | −29.19% |
| Q3 2019 | 2019-09-30 | $8.9M | −$7.8M | −46.75% |
| Q2 2019 | 2019-06-30 | $10.9M | −$8.2M | −42.85% |
| Q1 2019 | 2019-03-31 | $12.4M | $1.3M | +11.40% |
| Q4 2018 | 2018-12-31 | $14.3M | −$24,775 | −0.17% |
| Q3 2018 | 2018-09-30 | $16.7M | $592,669 | +3.69% |
| Q2 2018 | 2018-06-30 | $19.1M | $751,360 | +4.10% |
| Q1 2018 | 2018-03-31 | $11.2M | −$834,859 | −6.96% |
| Q4 2017 | 2017-12-31 | $14.3M | $4.6M | +47.01% |
| Q3 2017 | 2017-09-30 | $16.1M | $5.4M | +51.27% |
| Q2 2017 | 2017-06-30 | $18.3M | $5.5M | +43.26% |
| Q1 2017 | 2017-03-31 | $12.0M | −$315,561 | −2.56% |
| Q4 2016 | 2016-12-31 | $9.7M | $222,901 | +2.34% |
| Q3 2016 | 2016-09-30 | $10.6M | $530,470 | +5.26% |
| Q2 2016 | 2016-06-30 | $12.8M | $11.2M | +721.38% |
| Q1 2016 | 2016-03-31 | $12.3M | $9.8M | +383.57% |
| Q4 2015 | 2015-12-31 | $9.5M | $8.1M | +576.00% |
| Q3 2015 | 2015-09-30 | $10.1M | — | — |
| Q2 2015 | 2015-06-30 | $1.6M | — | — |
| Q1 2015 | 2015-03-31 | $2.5M | — | — |
| Q4 2014 | 2014-12-31 | $1.4M | — | — |
Kiora Pharmaceuticals total assets trends
Over the last five fiscal years, Kiora Pharmaceuticals's total assets increased from $15.3M to $24.3M, a change of $8.9M. The latest reported quarter, Q2 2026, shows $23.8M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kiora Pharmaceuticals source filings ↗